AI has embedded itself in every aspect of our technology and society.
Biological research and, in particular, drug discovery is no different in this respect. In fact, it is already apparent that AI will have a massive positive impact in shortening drug discovery timelines and improving the chances of success in identifying life-saving and life-changing drugs.
The potential is huge. And so are the challenges.
Frequently, progress in this sector is based on collaborations between companies in the tech and biotech/pharma spaces. However, this often involves very different sized companies with different outlooks and strategies when it comes to IP, commercial agreements, and regulation. This has the potential to create challenges for both sides.
Join us for a look at the questions that arise when tech meets bio and a discussion on how we can solve them.
The event will be kicked off with a keynote from Uzma Choudry of Octopus Ventures, one of the foremost investors in this space, with an overview of the AI drug discovery landscape and investment trends. After an overview of IP, regulatory and commercial topics by legal experts from Kilburn & Strode and Covington, we are excited to bring together representatives of companies of very different sizes that approach the meeting point of Tech and Bio from different sides. They will share with us their thoughts and debate how collaborations at the intersection between Tech and Bio can be optimised for success. If you would like to find out more about our panel, all information can be found below.
We hope you can join us!
Alexander Korenberg, Kilburn & Strode
Sarah Lau, Kilburn & Strode
Daniel Pavin, Covington
Uzma Choudry, Octopus Ventures
Liz Elmhirst, Achilles Therapeutics
Aline Charpentier, Bruntwood SciTech
Jason Rice, GSK
Anne Poupon, MAbSilico